Todd A Morrison1, Mark Figgie2, Andy O Miller3, Susan M Goodman4. 1. Jefferson Medical College, 1025 Walnut Street, Philadelphia, PA 19107 USA. 2. Department of Orthopedic Surgery, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021 USA. 3. Division of Infectious Diseases, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021 USA. 4. Department of Rheumatology, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021 USA.
Abstract
BACKGROUND: Prevention, early identification, and effective management of periprosthetic joint infection (PJI) in patients with inflammatory joint disease (IJD) present unique challenges for physicians. Discontinuing disease-modifying anti-rheumatoid drugs (DMARDs) perioperatively may reduce immunosuppression and infection risk at the expense of increasing disease flares. Interpreting traditional diagnostic markers of PJI can be difficult due to disease-related inflammation. PURPOSES: This review is designed to answer how to (1) manage immunosuppressive/DMARD therapy perioperatively, (2) diagnose PJI in patients with IJD, and (3) treat PJI in this population. METHODS: The PubMed database was searched for relevant articles with subsequent review by independent authors. RESULTS: While there is evidence to support the use of methotrexate perioperatively in RA patients, it remains unclear whether using anti-tumor necrosis factor medications perioperatively increases the risk of surgical site infections. Serum erythrocyte sedimentation rate and C-reactive protein can be useful for diagnosis of PJI in this population, but only as part of comprehensive workup that ultimately relies upon sampling of joint fluid. Management of PJI depends on several clinical factors including duration of infection and the likelihood of biofilm presence, the infecting organism, sensitivity to antibiotic therapy, and host immune status. The evidence suggests that two-stage revision or resection arthroplasty is more likely to eradicate infection, particularly when MRSA is the pathogen. CONCLUSION: Immunosuppression and baseline inflammatory changes in the IJD population can complicate the prevention, diagnosis, and treatment of PJI. Understanding the increase in risk associated with IJD and its treatment is essential for proper management when patients undergo lower extremity arthroplasty.
BACKGROUND: Prevention, early identification, and effective management of periprosthetic joint infection (PJI) in patients with inflammatory joint disease (IJD) present unique challenges for physicians. Discontinuing disease-modifying anti-rheumatoid drugs (DMARDs) perioperatively may reduce immunosuppression and infection risk at the expense of increasing disease flares. Interpreting traditional diagnostic markers of PJI can be difficult due to disease-related inflammation. PURPOSES: This review is designed to answer how to (1) manage immunosuppressive/DMARD therapy perioperatively, (2) diagnose PJI in patients with IJD, and (3) treat PJI in this population. METHODS: The PubMed database was searched for relevant articles with subsequent review by independent authors. RESULTS: While there is evidence to support the use of methotrexate perioperatively in RApatients, it remains unclear whether using anti-tumor necrosis factor medications perioperatively increases the risk of surgical site infections. Serum erythrocyte sedimentation rate and C-reactive protein can be useful for diagnosis of PJI in this population, but only as part of comprehensive workup that ultimately relies upon sampling of joint fluid. Management of PJI depends on several clinical factors including duration of infection and the likelihood of biofilm presence, the infecting organism, sensitivity to antibiotic therapy, and host immune status. The evidence suggests that two-stage revision or resection arthroplasty is more likely to eradicate infection, particularly when MRSA is the pathogen. CONCLUSION: Immunosuppression and baseline inflammatory changes in the IJD population can complicate the prevention, diagnosis, and treatment of PJI. Understanding the increase in risk associated with IJD and its treatment is essential for proper management when patients undergo lower extremity arthroplasty.
Entities:
Keywords:
inflammatory arthritis; periprosthetic joint infection; total joint arthroplasty
Authors: J Bohannon Mason; Thomas K Fehring; Susan M Odum; William L Griffin; Donna S Nussman Journal: J Arthroplasty Date: 2003-12 Impact factor: 4.757
Authors: Elie F Berbari; Douglas R Osmon; Mary C T Duffy; R N William Harmssen; Jayawant N Mandrekar; Arlen D Hanssen; James M Steckelberg Journal: Clin Infect Dis Date: 2005-12-06 Impact factor: 9.079
Authors: Veena K Ranganath; David A Elashoff; Dinesh Khanna; Grace Park; James B Peter; Harold E Paulus Journal: J Rheumatol Date: 2005-06 Impact factor: 4.666
Authors: Craig J Della Valle; Scott M Sporer; Joshua J Jacobs; Richard A Berger; Aaron G Rosenberg; Wayne G Paprosky Journal: J Arthroplasty Date: 2007-07-26 Impact factor: 4.757
Authors: Tim Bongartz; Christine S Halligan; Douglas R Osmon; Megan S Reinalda; William R Bamlet; Cynthia S Crowson; Arlen D Hanssen; Eric L Matteson Journal: Arthritis Rheum Date: 2008-12-15
Authors: Namrata Singh; Rajeshwari Nair; Michihiko Goto; Martha L Carvour; Ryan Carnahan; Elizabeth H Field; Petar Lenert; Mary Vaughan-Sarrazin; Marin L Schweizer; Eli N Perencevich Journal: Open Forum Infect Dis Date: 2019-10-19 Impact factor: 3.835
Authors: Lei Chu; You-Liang Ren; Jun-Song Yang; Jin Yang; Hang Zhou; Hai-Tao Jiang; Lei Shi; Ding-Jun Hao; Zhong-Liang Deng Journal: J Orthop Surg Res Date: 2020-04-25 Impact factor: 2.359